Effect of over-expressed LRIG3 on cell cycle and survival of glioma cells

Abstract

This study examined the effects of over-expression of leucine-rich repeats and immunoglobulin-like domains 3 (LRIG3) on the cell cycle and survival of human glioma cell line U87 and U251 and explored the possible mechanisms. The LRIG3 gene was transduced into U87 and U251 cells respectively by using lentivirus and the transduced cells were selected by puromycin. The changes in LRIG3 mRNA and protein levels were measured by RT-PCR and Western blotting. The apoptosis rate was detected by Annexin V-FITC/PI double labeling and the cell cycle was flow cytometrically analyzed. Compared with control cells, LRIG3 mRNA expression in U251 and U87 cells transduced with pLVX-DsRed-LRIG3-Monomer-N1 were increased by 77.6% and 129.7%, and LRIG3 protein expression was raised by 141.3% and 322.7%, respectively. Cell cycle analysis showed that LRIG3 over-expression increased the percentage of cells at G₀/G₁ phase (P<0.01). Over-expressed LRIG3 could significantly promote the apoptosis of U87 and U251 cells (P<0.05). These findings suggest that the over-expression of LRIG3 could arrest the cell cycle in G₀/G₁ phase, and promote apoptosis of U87 and U251 cells.

Keywords

glioma / leucine-rich repeats and immunoglobulin-like domains 3 / cell cycle / cell apoptosis

References

[1] KotliarovaS., PastorinoS., KovellL.C., et al.. Glycogen synthase kinase-3 inhibition induces glioma cell death through c-MYC, nuclear factor-kappaB, and glucose regulation. Cancer Res, 2008, 68(16): 6643-665

[2] XiongZ., CaoY., GuoD., et al.. Expression of EGFR and LRIG-1 in human trigeminal neurinoma. J Huazhong Univ Sci Technol [Med Sci], 2006, 26(1): 86-88

[3] YiW., HaapasaloH., HolmlundC., et al.. Expression of leucine-rich repeats and immunoglobulin-like domains (LRIG) proteins in human ependymoma relates to tumor location, WHO grade, and patient age. Clin Neuropathol, 2009, 28(1): 21-27

[4] NilssonJ., VallboC., GuoD., et al.. Cloning, characterization, and expression of human LIG1. Biochem Biophys Res Commun, 2001, 284(5): 1155-1161

[5] HolmlundC., NilssonJ., GuoD., et al.. Characterization and tissue-specific expression of human LRIG2. Gene, 2004, 332: 35-43

[6] GuoD., HolmlundC., HenrikssonR., HedmanH.. The LRIG gene family has three vertebrate paralogs widely expressed in human and mouse tissues and a homolog in Ascidiacea. Genomics, 2004, 84(1): 157-165

[7] GuoD., NilssonJ., HaapasaloH., et al.. Perinuclear leucine-rich repeats and immunoglobulin-like domain proteins (LRIG1-3) as prognostic indicators in astrocytic tumors. Acta Neuropathol, 2006, 111(3): 238-246

[8] CaiM., XieR., HanL., et al.. Effects of RNAi-mediated gene silencing of LRIG3 expression on cell cycle and survival of glioma cells. J Huazhong Univ Sci Technol [Med Sci], 2009, 29(1): 88-93

[9] WangB., HanL., ChenR., et al.. Downregulation of LRIG2 expression by RNA interference inhibits glioblastoma cell (GL15) growth, causes cell cycle redistribution, increases cell apoptosis and enhances cell adhesion and invasion in vitro. Cancer Biol Ther, 2009, 8(11): 1018-1023

[10] YangM., WangX.G., StoutJ.T., et al.. Expression of a recombinant human RGR opsin in lentivirus-transduced cultured cells. Mol Vis, 2000, 6: 237-242

[11] AnD.S., KungS.K., BonifacinoA., et al.. Lentivirus vector-mediated hematopoietic stem cell gene transfer of common gamma-chain cytokine receptor in rhesus macaques. J Virol, 2001, 75(8): 3547-3555

[12] KafriT.. Lentivirus vectors: difficulties and hopes before clinical trials. Curr Opin Mol Ther, 2001, 3(4): 316-326

[13] BesnierC., TakeuchiY., TowersG.. Restriction of lentivirus in monkeys. Proc Natl Acad Sci USA, 2002, 99(18): 11920-11925

[14] LottiF., MavilioF.. The choice of a suitable lentivirus vector: transcriptional targeting. Methods Mol Biol, 2003, 229: 17-27

[15] SakodaT., KasaharaN., KedesL.. Lentivirus vector-mediated gene transfer to cardiomyocytes. Methods Mol Biol, 2003, 219: 53-70

[16] HedmanH., HenrikssonR.. LRIG inhibitors of growth factor signalling-double-edged swords in human cancer. Eur J Cancer, 2007, 43(4): 676-682

[17] GuoD., HanL., ShuK., et al.. Down-regulation of leucine-rich repeats and immunoglobulin-like domain proteins (LRIG1-3) in HP75 pituitary adenoma cell line. J Huazhong Univ Sci Technol [Med Sci], 2007, 27(1): 91-94

[18] ZhaoH., TanegashimaK., RoH., et al.. Lrig3 regulates neural crest formation in Xenopus by modulating Fgf and Wnt signaling pathways. Development, 2008, 135(7): 1283-1293

[19] AbrairaV.E., DelR.T., TuckerA.F., et al.. Cross-repressive interactions between Lrig3 and netrin 1 shape the architecture of the inner ear. Development, 2008, 135(24): 4091-4099

[20] VermeulenK., Van BockstaeleD.R., BernemanZ.N.. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif, 2003, 36(3): 131-149

[21] HanseE.A., NelsenC.J., GogginM.M., et al.. Cdk2 plays a critical role in hepatocyte cell cycle progression and survival in the setting of cyclin D1 expression in vivo. Cell Cycle, 2009, 8(17): 2802-2809